About
Stealth Mode Startup
Ionara Bio is developing novel, proprietary small molecules that target and block the TRPV2 channel—a key driver of inflammatory responses, particularly those involving macrophages, that impair cardiac structure and function following acute myocardial infarction (AMI). The company’s lead candidate, a first-in-class TRPV2 inhibitor, is designed to improve cardiac function and reduce pathological cardiac fibrosis, ultimately leading to significantly enhanced post-AMI recovery.
Identity
| Name | Ionara Bio |
|---|---|
| Slug | ionara-bio |
| Type / kind | startup |
| Source _id | FV8d9B2odGD4SztOhSmHFfeQs1Ttrz93IL4AvYikox1G81NQqpx5nu |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Ness Ziona |
| HQ address | Ness Ziona, Israel |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical Biotechnology
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesHealthcareProviders
Tags
stealthmodecardiology
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}